2018 Gene Therapy in Oncology - There is a Significant Opportunity for Developing Combination Regimens - ResearchAndMarkets.com
Aug. 23, 2018
DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The "Gene Therapy in Oncology" report has been added to ResearchAndMarkets.com's offering.
Currently only small size biotech and pharmaceutical companies dominate the pipeline for cancer gene therapies. With J&J having the exclusive worldwide rights to develop and commercialize Geron's imetelstat and AstraZeneca the only large pharmaceutical company with an in-house gene therapy in late stage clinical development; Merck & Co. and BMS are evaluating their respective in-house CPI therapies with many of the Phase II and III candidates in the cancer gene therapy pipeline.
KOLs see a huge potential for cancer gene therapies, particularly in combination with immune CPIs. To this end, there is a significant opportunity for developing combination regimens as half of the Phase III pipeline is evaluated as a monotherapy and only one candidate is evaluated in combination with a CPI in their pivotal studies.
ScopeOverview of Cancer Gene Therapy: What are the gene transfer methods and strategies used in oncology. Cancer Gene Therapy in the 8MM: What is the regulatory framework concerning development and approval of cancer gene therapies in the 8MM and what are the currently marketed gene therapies in the oncology space in the 8MM. Clinical Development of Gene Therapies in Oncology: What are the late stage pipeline cancer gene therapies. Clinical Trial Mapping and Design: How are gene therapies positioned in the oncology space: what are the oncology indications they are targeting and which other therapeutic agents are they being evaluated in combination with. Market Outlook for Cancer Gene Therapies in Oncology: When are cancer gene therapies expected to be marketed for various oncology indications, what are some of the most promising candidates, and what are some challenges that cancer gene therapies are expected to face following their launch. Reimbursement of Gene Therapies in Oncology: What are the challenges associated with reimbursement of novel cancer therapies and some strategies to contain the cost of cancer gene therapies.
Companies FeaturedAdvantage Advaxis Immunotherapies Amgen Ascend Biopharmaceuticals AstraZeneca Bio-Path Holdings Bristol-Myers Squibb Cold Genesys CRISPR Therapeutics Daiichi Sankyo DNAtrix Editas Medicine Geron Corp Idera Pharmaceuticals Intellia Therapeutics Johnson & Johnson Marsala Biotech Merck & Co Mologen AG MTG Biotherapeutics Oncolytics Biotech Oncosec Oncotelic Shanghai Sunway Biotech Shenzhen SiBiono GeneTech Silenseed Sillajen Biotherapeutics SynerGene Therapeutics Takara Holdings Targovax Tocagen UniQure Vascular Biogenics Ziopharm Oncology
For more information about this report visit https://www.researchandmarkets.com/research/tzbz5k/2018_gene_therapy?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005678/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/23/2018 02:42 PM/DISC: 08/23/2018 02:42 PM